JP2018529380A5 - - Google Patents

Download PDF

Info

Publication number
JP2018529380A5
JP2018529380A5 JP2018534523A JP2018534523A JP2018529380A5 JP 2018529380 A5 JP2018529380 A5 JP 2018529380A5 JP 2018534523 A JP2018534523 A JP 2018534523A JP 2018534523 A JP2018534523 A JP 2018534523A JP 2018529380 A5 JP2018529380 A5 JP 2018529380A5
Authority
JP
Japan
Prior art keywords
flt3
car
nucleic acid
isolated
isolated nucleic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018534523A
Other languages
English (en)
Japanese (ja)
Other versions
JP7054924B2 (ja
JP2018529380A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/053577 external-priority patent/WO2017053889A2/en
Publication of JP2018529380A publication Critical patent/JP2018529380A/ja
Publication of JP2018529380A5 publication Critical patent/JP2018529380A5/ja
Priority to JP2021189789A priority Critical patent/JP2022046461A/ja
Application granted granted Critical
Publication of JP7054924B2 publication Critical patent/JP7054924B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018534523A 2015-09-23 2016-09-23 免疫療法のためのflt3指向car細胞 Expired - Fee Related JP7054924B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021189789A JP2022046461A (ja) 2015-09-23 2021-11-24 免疫療法のためのflt3指向car細胞

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562222695P 2015-09-23 2015-09-23
US62/222,695 2015-09-23
PCT/US2016/053577 WO2017053889A2 (en) 2015-09-23 2016-09-23 Flt3 directed car cells for immunotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021189789A Division JP2022046461A (ja) 2015-09-23 2021-11-24 免疫療法のためのflt3指向car細胞

Publications (3)

Publication Number Publication Date
JP2018529380A JP2018529380A (ja) 2018-10-11
JP2018529380A5 true JP2018529380A5 (https=) 2019-10-31
JP7054924B2 JP7054924B2 (ja) 2022-04-15

Family

ID=58387435

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018534523A Expired - Fee Related JP7054924B2 (ja) 2015-09-23 2016-09-23 免疫療法のためのflt3指向car細胞
JP2021189789A Pending JP2022046461A (ja) 2015-09-23 2021-11-24 免疫療法のためのflt3指向car細胞

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021189789A Pending JP2022046461A (ja) 2015-09-23 2021-11-24 免疫療法のためのflt3指向car細胞

Country Status (9)

Country Link
US (2) US10961312B2 (https=)
EP (2) EP3569244A1 (https=)
JP (2) JP7054924B2 (https=)
KR (1) KR20180053744A (https=)
CN (1) CN109310744A (https=)
AU (2) AU2016326721C1 (https=)
CA (1) CA2999037A1 (https=)
HK (1) HK1258921A1 (https=)
WO (1) WO2017053889A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3569244A1 (en) * 2015-09-23 2019-11-20 CytoImmune Therapeutics, LLC Flt3 directed car cells for immunotherapy
CA3025516A1 (en) 2016-05-27 2017-11-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Flt3-specific chimeric antigen receptors and methods using same
AU2017382883B2 (en) 2016-12-21 2024-07-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies specific for FLT3 and uses thereof
BR112019017767A2 (pt) 2017-02-27 2020-04-07 Juno Therapeutics Inc composições, artigos de fabricação e métodos relacionados à dosagem em terapia celular
SG10202108528QA (en) * 2017-06-02 2021-09-29 Pfizer Chimeric antigen receptors targeting flt3
MY201312A (en) 2017-06-02 2024-02-16 Pfizer Antibodies specific for flt3 and their uses
AU2018275894B2 (en) 2017-06-02 2025-04-24 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
EP3661511A1 (en) * 2017-08-01 2020-06-10 Julius-Maximilians-Universität Würzburg Use of flt3 car-t cells and flt3 inhibitors to treat acute myeloid leukemia
US20210130775A1 (en) * 2017-08-02 2021-05-06 Autolus Limited Cells expressing a chimeric antigen receptor or engineered tcr and comprising a nucleotide sequence which is selectively expressed
US12258580B2 (en) 2017-11-01 2025-03-25 Juno Therapeutics, Inc. Process for generating therapeutic compositions of engineered cells
KR20250067182A (ko) * 2017-11-10 2025-05-14 주라 바이오, 인크. 주 조직적합성 복합체-기반 키메라 수용체 및 자가면역 질병을 치료하기 위한 이의 용도
CN109988759A (zh) * 2017-12-29 2019-07-09 上海细胞治疗研究院 一种在t细胞中具有高转录活性的嵌合启动子
US20190328785A1 (en) * 2018-04-30 2019-10-31 The Board Of Regents Of The University Of Oklahoma Flt3-binding chimeric antigen receptors, cells, and uses thereof
CN110305847B (zh) * 2018-07-27 2021-05-18 赛诺生(深圳)基因产业发展有限公司 一种用于治疗肿瘤的基因工程细胞
CN109134665B (zh) * 2018-08-24 2021-06-11 上海先博生物科技有限公司 一种基于单域抗体的bcma嵌合抗原受体及应用
PT3886875T (pt) * 2018-11-30 2024-06-27 Juno Therapeutics Inc Métodos para tratamento utilizando terapia celular adotiva
SG11202104352XA (en) 2018-12-18 2021-05-28 Boehringer Ingelheim Io Canada Inc Flt3 agonist antibodies and uses thereof
TW202110873A (zh) 2019-04-30 2021-03-16 美商聖堤生物科技股份有限公司 嵌合受體及其使用方法
EP4032972A4 (en) * 2019-09-18 2024-07-24 Slbigen Inc. GENETICALLY MODIFIED NK CELL LINE TRANSDUCED WITH A GENE ENCODING A NEW CHIMERIC ANTIGEN RECEPTOR AND ITS USE
KR102287180B1 (ko) 2019-10-01 2021-08-09 충북대학교 산학협력단 Cd138에 특이적으로 결합하는 키메릭 항원 수용체, 이를 발현하는 면역세포 및 이의 항암 용도
JP7755597B2 (ja) * 2020-04-09 2025-10-16 オートラス リミテッド 細胞
AU2021256053A1 (en) * 2020-04-17 2022-11-10 City Of Hope FLT3-targeted chimeric antigen receptor modified cells for treatment of FLT3-positive malignancies
CN111647071B (zh) * 2020-06-17 2023-05-05 深圳豪石生物科技有限公司 识别靶细胞表面抗原的t细胞受体及其组合物
CN116410315A (zh) * 2021-12-31 2023-07-11 博生吉医药科技(苏州)有限公司 一种新型靶向人flt3的嵌合抗原受体修饰的t细胞的构建及应用

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
WO1992022324A1 (en) 1991-06-14 1992-12-23 Xoma Corporation Microbially-produced antibody fragments and their conjugates
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1995015982A2 (en) 1993-12-08 1995-06-15 Genzyme Corporation Process for generating specific antibodies
DE69534347T2 (de) 1994-01-31 2006-05-24 Trustees Of Boston University, Boston Bibliotheken aus Polyklonalen Antikörpern
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
GB9416721D0 (en) 1994-08-18 1994-10-12 Short Brothers Plc A bias yarn assembly forming device
US5712149A (en) 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
DE19608769C1 (de) 1996-03-07 1997-04-10 Univ Eberhard Karls Antikörper BV10A4H2
US6924123B2 (en) 1996-10-29 2005-08-02 Oxford Biomedica (Uk) Limited Lentiviral LTR-deleted vector
ES2327382T3 (es) 1999-07-20 2009-10-29 Morphosys Ag Metodos para presentar (poli)peptidos/proteinas en particulas de bacteriofagos a traves de enlaces disulfuro.
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
KR20030032922A (ko) 2000-02-24 2003-04-26 싸이트 테라피스 인코포레이티드 세포의 동시 자극 및 농축
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7419829B2 (en) 2000-10-06 2008-09-02 Oxford Biomedica (Uk) Limited Vector system
IL157335A0 (en) 2001-03-13 2004-02-19 Novartis Ag Lentiviral packaging constructs
US8034904B2 (en) * 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
SI1583830T1 (sl) 2003-01-07 2006-12-31 Symphogen As Postopek za pripravo rekombinantnih poliklonskih proteinov
US20130266551A1 (en) 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
AR071891A1 (es) 2008-05-30 2010-07-21 Imclone Llc Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
DK2516468T3 (en) * 2009-12-23 2016-05-23 Synimmune Gmbh ANTI-FLT3 ANTIBODIES AND METHODS FOR USING THESE
US9089520B2 (en) * 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
US9233125B2 (en) 2010-12-14 2016-01-12 University Of Maryland, Baltimore Universal anti-tag chimeric antigen receptor-expressing T cells and methods of treating cancer
WO2013044225A1 (en) 2011-09-22 2013-03-28 The Trustees Of The University Of Pennsylvania A universal immune receptor expressed by t cells for the targeting of diverse and multiple antigens
EP2817330B1 (en) 2012-02-22 2020-07-08 The Trustees of the University of Pennsylvania Use of icos-based cars to enhance antitumor activity and car persistence
MX367730B (es) * 2012-09-04 2019-09-04 Cellectis Receptor de antigeno quimerico multi-cadena y usos del mismo.
CN113005091A (zh) 2013-02-06 2021-06-22 细胞基因公司 具有改进特异性的修饰的t淋巴细胞
DK2956175T3 (da) 2013-02-15 2017-11-27 Univ California Kimærisk antigenreceptor og fremgangsmåder til anvendelse deraf
ES2671004T3 (es) * 2013-03-07 2018-06-04 Baylor College Of Medicine Dirección a CD138 en cáncer
US9657105B2 (en) 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
UY35468A (es) * 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
CN105814083A (zh) 2013-10-15 2016-07-27 加州生物医学研究所 嵌合抗原受体t细胞开关和其用途
CN105829349B (zh) 2013-10-15 2023-02-03 斯克利普斯研究所 肽嵌合抗原受体t细胞开关和其用途
WO2015112626A1 (en) * 2014-01-21 2015-07-30 June Carl H Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
US20170335281A1 (en) * 2014-03-15 2017-11-23 Novartis Ag Treatment of cancer using chimeric antigen receptor
CN104091269A (zh) 2014-06-30 2014-10-08 京东方科技集团股份有限公司 一种虚拟试衣方法及虚拟试衣系统
KR20170032406A (ko) 2014-07-15 2017-03-22 주노 쎄러퓨티크스 인코퍼레이티드 입양 세포 치료를 위한 조작된 세포
CA2964958A1 (en) 2014-10-31 2016-05-06 The Trustees Of The University Of Pennsylvania Methods and compositions for modified t cells
EP3234144B1 (en) 2014-12-15 2020-08-26 Bellicum Pharmaceuticals, Inc. Methods for controlled elimination of therapeutic cells
HK1245827B (en) 2014-12-15 2020-06-19 Board Of Regents Of The University Of Texas System Methods for controlled activation or elimination of therapeutic cells
EP3268038B1 (en) 2015-03-09 2021-05-05 Agensys, Inc. Antibody drug conjugates (adc) that bind to flt3 proteins
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究(慕尼黑)公司 Flt3及cd3抗體構築體
US10286092B2 (en) * 2015-08-25 2019-05-14 Ucl Business Plc Detecting a therapeutic cell
EP3569244A1 (en) * 2015-09-23 2019-11-20 CytoImmune Therapeutics, LLC Flt3 directed car cells for immunotherapy
MY201312A (en) 2017-06-02 2024-02-16 Pfizer Antibodies specific for flt3 and their uses
WO2020010284A1 (en) 2018-07-04 2020-01-09 Cytoimmune Therapeutics, LLC Compositions and methods for immunotherapy targeting flt3, pd-1, and/or pd-l1

Similar Documents

Publication Publication Date Title
JP2018529380A5 (https=)
JP2017537622A5 (https=)
Barrow et al. The natural cytotoxicity receptors in health and disease
JP2016502512A5 (https=)
RU2014118555A (ru) Химерные антигенные рецепторы к cd22
Eagle et al. ULBP6/RAET1L is an additional human NKG2D ligand
Schildberg et al. Coinhibitory pathways in the B7-CD28 ligand-receptor family
Severson et al. Junctional adhesion molecule A interacts with Afadin and PDZ-GEF2 to activate Rap1A, regulate β1 integrin levels, and enhance cell migration
JP2014534207A5 (https=)
Ito et al. Killer cell lectin-like receptor G1 binds three members of the classical cadherin family to inhibit NK cell cytotoxicity
Cosman et al. ULBPs, novel MHC class I–related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor
JP2020529841A5 (https=)
JP2022109953A5 (https=)
JP2018505139A5 (https=)
JP2022113880A (ja) 免疫調節性融合タンパク質およびその使用
JP2021506243A5 (https=)
RU2017130985A (ru) Фармацевтическая композиция и способ снижения ингибирующего эффекта pd-l1 на т-клетки человека
FI3429618T3 (fi) Immuunijäjestelmän tarkistuspisteen modulaattorin ja soluun tunkeutuvan peptidin, cargon ja tlr-peptidiagonistin kompleksin yhdistelmä lääketieteelliseen käyttöön
HRP20220799T1 (hr) Klaudin-18-2-specifični imunoreceptori i stanični epitopi t
JP2017513478A5 (https=)
JP2017518037A5 (https=)
JP2021505663A5 (https=)
GB2541599A (en) Nucleic acid for coding chimeric antigen receptor protein and T lymphocyte for expression of chimeric antigen receptor protein
JP2018513687A5 (https=)
IL292650B1 (en) COSTIMULATORY CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING IL13Ra2